AN1284 attenuates steatosis, lipogenesis, and fibrosis in mice with pre-existing non-alcoholic steatohepatitis and directly affects aryl hydrocarbon receptor in a hepatic cell line

Non-alcoholic steatohepatitis (NASH) is an aggressive form of fatty liver disease with hepatic inflammation and fibrosis for which there is currently no drug treatment. This study determined whether an indoline derivative, AN1284, which significantly reduced damage in a model of acute liver disease, can reverse steatosis and fibrosis in mice with pre-existing NASH and explore its mechanism of action. The mouse model of dietary-induced NASH reproduces most of the liver pathology seen in human subjects. This was confirmed by RNA-sequencing analysis. The Western diet, given for 4 months, caused steatosis, inflammation, and liver fibrosis. AN1284 (1 mg or 5 mg/kg/day) was administered for the last 2 months of the diet by micro-osmotic-pumps (mps). Both doses significantly decreased hepatic damage, liver weight, hepatic fat content, triglyceride, serum alanine transaminase, and fibrosis. AN1284 (1 mg/kg/day) given by mps or in the drinking fluid significantly reduced fibrosis produced by carbon tetrachloride injections. In human HUH7 hepatoma cells incubated with palmitic acid, AN1284 (2.1 and 6.3 ng/ml), concentrations compatible with those in the liver of mice treated with AN1284, decreased lipid formation by causing nuclear translocation of the aryl hydrocarbon receptor (AhR). AN1284 downregulated fatty acid synthase (FASN) and sterol regulatory element-binding protein 1c (SREBP-1c) and upregulated Acyl-CoA Oxidase 1 and Cytochrome P450-a1, genes involved in lipid metabolism. In conclusion, chronic treatment with AN1284 (1mg/kg/day) reduced pre-existing steatosis and fibrosis through AhR, which affects several contributors to the development of fatty liver disease. Additional pathways are also influenced by AN1284 treatment.

[1]  J. Friedman,et al.  Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease , 2023, Receptors.

[2]  W. Xie,et al.  Atypical functions of xenobiotic receptors in lipid and glucose metabolism , 2022, Medical review.

[3]  J. Friedman,et al.  Cinnabarinic Acid Provides Hepatoprotection Against Nonalcoholic Fatty Liver Disease , 2022, The Journal of Pharmacology and Experimental Therapeutics.

[4]  H. Tilg,et al.  Current therapies and new developments in NASH , 2022, Gut.

[5]  F. Tacke,et al.  Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease , 2022, International journal of molecular sciences.

[6]  J Zhang,et al.  Role of the Aryl Hydrocarbon Receptor and Gut Microbiota-Derived Metabolites Indole-3-Acetic Acid in Sulforaphane Alleviates Hepatic Steatosis in Mice , 2021, Frontiers in Nutrition.

[7]  A. Carambia,et al.  The aryl hydrocarbon receptor in liver inflammation , 2021, Seminars in Immunopathology.

[8]  A. Nudelman,et al.  Comparison of the tissue distribution and metabolism of AN1284, a potent anti-inflammatory agent, after subcutaneous and oral administration in mice , 2021, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  A. Moschetta,et al.  Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH , 2021, Cellular and molecular gastroenterology and hepatology.

[10]  F. Tacke,et al.  Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities , 2020, Cellular & molecular immunology.

[11]  S. Della Torre.  Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling , 2020, Frontiers in Endocrinology.

[12]  P. Rada,et al.  Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? , 2020, Cell Death & Disease.

[13]  M. Weitman,et al.  A Novel Indoline Derivative Ameliorates Diabesity-Induced Chronic Kidney Disease by Reducing Metabolic Abnormalities , 2020, Frontiers in Endocrinology.

[14]  S. Romero-Zerbo,et al.  The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease , 2020, Frontiers in Endocrinology.

[15]  Shuyu Li,et al.  Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis , 2020, Frontiers in Medicine.

[16]  R. DeFronzo,et al.  GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) , 2020, Expert opinion on investigational drugs.

[17]  T. Vanhaecke,et al.  Anti-NASH Drug Development Hitches a Lift on PPAR Agonism , 2019, Cells.

[18]  D. Calvisi,et al.  Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma , 2019, Front. Oncol..

[19]  G. Carpino,et al.  Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD , 2019, Hepatology.

[20]  F. Nigsch,et al.  Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model , 2019, Hepatology communications.

[21]  U. Kaul,et al.  New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence , 2019, Cardiovascular Diabetology.

[22]  R. Schwabe,et al.  Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. , 2019, Gastroenterology.

[23]  D. Schuppan,et al.  Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis , 2019, Hepatology.

[24]  V. Dirsch,et al.  Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR. , 2018, Biotechnology advances.

[25]  Xiangdong Gao,et al.  A long‐acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non‐alcoholic steatohepatitis partly through an FGF21‐adiponectin‐IL17A pathway , 2018, British journal of pharmacology.

[26]  A. Nudelman,et al.  Synthesis and Biological Evaluation of Derivatives of Indoline as Highly Potent Antioxidant and Anti-inflammatory Agents. , 2018, Journal of medicinal chemistry.

[27]  B. Aronow,et al.  Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease. , 2018, JCI insight.

[28]  Gianluca Svegliati-Baroni,et al.  Lipotoxicity and the gut-liver axis in NASH pathogenesis. , 2018, Journal of hepatology.

[29]  F. Quintana,et al.  Regulation of the Immune Response by the Aryl Hydrocarbon Receptor. , 2018, Immunity.

[30]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[31]  M. Weinstock,et al.  Indoline derivatives mitigate liver damage in a mouse model of acute liver injury , 2017, Pharmacological reports : PR.

[32]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[33]  E. Levy,et al.  Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. , 2017, Antioxidants & redox signaling.

[34]  E. Park,et al.  (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation. , 2016, European journal of pharmacology.

[35]  Hongliang Li,et al.  Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. , 2016, Journal of hepatology.

[36]  Krishnamurthy V. Nemani,et al.  Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1. , 2016, Toxicology and applied pharmacology.

[37]  L. Desai,et al.  Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis , 2015, Redox biology.

[38]  Patrice D. Cani,et al.  Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling , 2015, Cell metabolism.

[39]  Hideji Nakamura,et al.  Liver fibrosis markers of nonalcoholic steatohepatitis. , 2015, World journal of gastroenterology.

[40]  Xiaochao Ma,et al.  Activation of aryl hydrocarbon receptor dissociates fatty liver from insulin resistance by inducing fibroblast growth factor 21 , 2015, Hepatology.

[41]  A. Nudelman,et al.  Synthesis and in vitro evaluation of anti-inflammatory activity of ester and amine derivatives of indoline in RAW 264.7 and peritoneal macrophages. , 2014, Bioorganic & medicinal chemistry letters.

[42]  Fabian Kiessling,et al.  CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis , 2014, Gut.

[43]  T. Kishimoto,et al.  The roles of aryl hydrocarbon receptor in immune responses. , 2013, International immunology.

[44]  K. Kang,et al.  The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease. , 2010, The British journal of nutrition.

[45]  Hang Sun,et al.  Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease , 2010, Hepatology international.

[46]  G. Kristiansen,et al.  Expression of fatty acid synthase in nonalcoholic fatty liver disease. , 2010, International journal of clinical and experimental pathology.

[47]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.